Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Account Payables (2016 - 2025)

Regenxbio (RGNX) has 12 years of Change in Account Payables data on record, last reported at -$1.9 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 161.26% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached -$2.3 million, down 682.19%, while the annual FY2025 figure was -$2.3 million, 682.19% down from the prior year.
  • Change in Account Payables reached -$1.9 million in Q4 2025 per RGNX's latest filing, down from $694000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $16.8 million in Q1 2022 and bottomed at -$14.9 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $555950.0, with a median of $957000.0 recorded in 2023.
  • The widest YoY moves for Change in Account Payables: up 5926.98% in 2022, down 542.49% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$8.8 million in 2021, then soared by 121.65% to $1.9 million in 2022, then tumbled by 36.03% to $1.2 million in 2023, then skyrocketed by 149.02% to $3.0 million in 2024, then crashed by 161.26% to -$1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.9 million in Q4 2025, $694000.0 in Q3 2025, and $2.5 million in Q2 2025.